(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 437.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Oculis Holding Ag's revenue in 2026 is $1,537,179.On average, 12 Wall Street analysts forecast OCS's revenue for 2026 to be $360,431,267, with the lowest OCS revenue forecast at $0, and the highest OCS revenue forecast at $2,496,230,056. On average, 9 Wall Street analysts forecast OCS's revenue for 2027 to be $3,576,712,074, with the lowest OCS revenue forecast at $159,109,298, and the highest OCS revenue forecast at $13,333,521,518.
In 2028, OCS is forecast to generate $16,048,932,750 in revenue, with the lowest revenue forecast at $2,913,080,181 and the highest revenue forecast at $44,232,848,684.